CN109293782A - 融合多肽及使用方法 - Google Patents

融合多肽及使用方法 Download PDF

Info

Publication number
CN109293782A
CN109293782A CN201811243025.9A CN201811243025A CN109293782A CN 109293782 A CN109293782 A CN 109293782A CN 201811243025 A CN201811243025 A CN 201811243025A CN 109293782 A CN109293782 A CN 109293782A
Authority
CN
China
Prior art keywords
seq
leu
spiral
amino acid
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811243025.9A
Other languages
English (en)
Chinese (zh)
Inventor
刘宏宇
赵明治
孙赫彤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deyi Sunshine Biotechnology (beijing) Co Ltd
Original Assignee
Deyi Sunshine Biotechnology (beijing) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deyi Sunshine Biotechnology (beijing) Co Ltd filed Critical Deyi Sunshine Biotechnology (beijing) Co Ltd
Priority to CN201811243025.9A priority Critical patent/CN109293782A/zh
Publication of CN109293782A publication Critical patent/CN109293782A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201811243025.9A 2014-01-08 2014-01-08 融合多肽及使用方法 Pending CN109293782A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811243025.9A CN109293782A (zh) 2014-01-08 2014-01-08 融合多肽及使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201480003114.XA CN104968673B (zh) 2014-01-08 2014-01-08 融合多肽及使用方法
PCT/CN2014/070328 WO2015103749A1 (en) 2014-01-08 2014-01-08 Fusion polypeptides and methods of use
CN201811243025.9A CN109293782A (zh) 2014-01-08 2014-01-08 融合多肽及使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480003114.XA Division CN104968673B (zh) 2014-01-08 2014-01-08 融合多肽及使用方法

Publications (1)

Publication Number Publication Date
CN109293782A true CN109293782A (zh) 2019-02-01

Family

ID=53523446

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811243025.9A Pending CN109293782A (zh) 2014-01-08 2014-01-08 融合多肽及使用方法
CN201480003114.XA Active CN104968673B (zh) 2014-01-08 2014-01-08 融合多肽及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480003114.XA Active CN104968673B (zh) 2014-01-08 2014-01-08 融合多肽及使用方法

Country Status (5)

Country Link
US (2) US10246501B2 (2)
EP (2) EP3954714A1 (2)
JP (1) JP6730926B2 (2)
CN (2) CN109293782A (2)
WO (1) WO2015103749A1 (2)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112694526A (zh) * 2020-05-27 2021-04-23 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN112870336A (zh) * 2021-02-24 2021-06-01 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂
WO2021238302A1 (zh) * 2020-05-27 2021-12-02 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN115385998A (zh) * 2021-04-13 2022-11-25 杭州先为达生物科技有限公司 稳定的iii型干扰素蛋白及其融合蛋白

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109293782A (zh) 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
MX2019003744A (es) * 2016-09-30 2019-10-30 Univ Leland Stanford Junior Interferones de variante tipo iii y sintecinas.
JP2019107021A (ja) * 2019-03-05 2019-07-04 プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031316A (zh) * 2004-07-29 2007-09-05 津莫吉尼蒂克斯公司 Il－28和il－29治疗癌症和自身免疫性疾病的用途
CN101821287A (zh) * 2007-08-08 2010-09-01 埃斯特瑞恩有限公司 干扰素融合蛋白
CN101918440A (zh) * 2007-09-20 2010-12-15 联邦科学技术研究组织 新的禽类细胞因子及编码其的遗传序列

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5939286A (en) 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
DE60135393D1 (de) 2000-06-30 2008-09-25 Zymogenetics Inc Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP2251352A1 (en) 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogeneous preparations of IL-28 and IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
JP2008508310A (ja) 2004-07-29 2008-03-21 ザイモジェネティクス， インコーポレイテッド がんおよび自己免疫障害を治療するためのｉｌ−２８およびｉｌ−２９の使用法
AU2005229674B2 (en) 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
CA2625208A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
AU2009255994B2 (en) * 2008-06-05 2014-07-17 Bristol-Myers Squibb Company Use of pegylated Type III Interferons for the treatment of hepatitis C
US20110263484A1 (en) 2008-10-13 2011-10-27 Zymogenetics, Inc. Single chain fc type iii interferons and methods of using same
EP3604555B1 (en) 2011-10-14 2024-12-25 President and Fellows of Harvard College Sequencing by structure assembly
WO2013087727A1 (en) * 2011-12-12 2013-06-20 Institut Pasteur New efficient interferon-based treating methods
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
CN109293782A (zh) 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031316A (zh) * 2004-07-29 2007-09-05 津莫吉尼蒂克斯公司 Il－28和il－29治疗癌症和自身免疫性疾病的用途
CN101821287A (zh) * 2007-08-08 2010-09-01 埃斯特瑞恩有限公司 干扰素融合蛋白
CN101918440A (zh) * 2007-09-20 2010-12-15 联邦科学技术研究组织 新的禽类细胞因子及编码其的遗传序列

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112694526A (zh) * 2020-05-27 2021-04-23 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
WO2021238302A1 (zh) * 2020-05-27 2021-12-02 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN115667291A (zh) * 2020-05-27 2023-01-31 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN115667291B (zh) * 2020-05-27 2025-08-05 杭州先为达生物科技股份有限公司 一种白细胞介素29突变体蛋白
CN112870336A (zh) * 2021-02-24 2021-06-01 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂
CN112870336B (zh) * 2021-02-24 2022-06-14 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂
WO2022178922A1 (zh) * 2021-02-24 2022-09-01 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂
CN115385998A (zh) * 2021-04-13 2022-11-25 杭州先为达生物科技有限公司 稳定的iii型干扰素蛋白及其融合蛋白

Also Published As

Publication number Publication date
CN104968673B (zh) 2018-11-02
WO2015103749A1 (en) 2015-07-16
EP3092248B1 (en) 2021-06-23
US11242371B2 (en) 2022-02-08
CN104968673A (zh) 2015-10-07
US10246501B2 (en) 2019-04-02
JP6730926B2 (ja) 2020-07-29
EP3954714A1 (en) 2022-02-16
EP3092248A1 (en) 2016-11-16
EP3092248A4 (en) 2017-06-28
US20170022259A1 (en) 2017-01-26
US20190382461A1 (en) 2019-12-19
JP2017503505A (ja) 2017-02-02

Similar Documents

Publication Publication Date Title
CN104968673B (zh) 融合多肽及使用方法
ES2822584T3 (es) Inducción de dinucleótidos cíclicos del interferón tipo I
Kang et al. A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma
JP2022095641A (ja) 条件的活性型ポリペプチド及びそれを生成する方法
EP1728863A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
EA022932B1 (ru) Димерные слитые белки vstm3 и связанные с ними композиции и способы
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
EA021867B1 (ru) Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций
WO2006031811A3 (en) Glycopegylated interferon alpha
CN107106655A (zh) 使用白细胞介素‑10治疗疾病和病症的方法
EP4295917A2 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
JP2024540977A (ja) ジスルフィドオリゴ糖化合物及び複合体
CN101432428B (zh) 重组人干扰素样蛋白
CN1269013A (zh) 呈递多个活性部分的分子
CN107849091A (zh) 能够在人脂肪衍生的干细胞和肝细胞中抑制丙肝病毒复制的肽及其衍生物
CA2432971A1 (en) Polypeptides
JP7712982B2 (ja) 融合ポリペプチドおよび使用方法
BR9707142A (pt) Polinucleotìdeo purificado, dna, vetor, célula hospedeira, linhagem celular de hibridoma, anticorpo monoclonal, processos para produzir exodus, para aumentar a resistência à infecção por vìrus de imonudeficiência humana (hiv), para tratamento de infecção por vìrus de imonodeficiência humana (hiv), para proteção de células progenitoras de medula óssea contra os efeitos citotóxicos e para tratamento de doenças mieloproliferativas, e, uso de produto de proteina de exodus.
Huang et al. Exploring structure-directed immunogenic cytotoxicity of arginine-rich peptides for cytolysis-induced immunotherapy of cancer
CN107849151A (zh) 融合多肽及使用方法
KR20020068260A (ko) β-2',3'-디데하이드로-2',3'-디데옥시-5-플루오로사이티딘에 의해 선택된 ＨＩＶ-1 돌연변이
Yeo et al. Nanoscale Horizons
Opdenakker et al. Applications of glycobiology: biological and immunological effects of a chemically modified amylose-derivative
HK40104832A (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
TWI328011B (en) Recombinant super-compound interferon

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190201